Stay updated on Nivolumab Ibrutinib in CLL Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Ibrutinib in CLL Clinical Trial page.

Latest updates to the Nivolumab Ibrutinib in CLL Clinical Trial page
- ChecktodayChange DetectedRevision tag updated from v3.3.3 to v3.3.4 on the page. There are no visible changes to the study details or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedAdded a dedicated Locations section with Texas as a study site. The previous Texas Locations entry was removed and the page revision updated to v3.3.3 (HHS Vulnerability Disclosure link removed).SummaryDifference0.2%

- Check50 days agoChange DetectedThe Publications section now displays auto-filled PubMed notes and includes a new revision label (v3.3.2). The older PubMed-source description was removed and replaced with the updated revision tag (v3.2.0).SummaryDifference0.1%

- Check57 days agoChange DetectedThe page no longer displays a notice about government funding and NIH operations status, which was a meta-information banner rather than core study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check72 days agoChange DetectedNo notable changes detected; the page content and layout remain focused on the NCT02420912 study details.SummaryDifference0.4%

- Check100 days agoChange DetectedPage now includes a government funding status notice and new version v3.2.0; a disease term (B-cell chronic lymphocytic leukemia) was removed.SummaryDifference3%

Stay in the know with updates to Nivolumab Ibrutinib in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Ibrutinib in CLL Clinical Trial page.